Evidence map›Paper›PMID 37066184›Full record

ArticlebioRxiv : the preprint server for biology2023

Triggering receptor expressed on myeloid cells 2 (TREM2) regulates phagocytosis in glioblastoma.

Mekenzie M Peshoff, Pravesh Gupta, Rakesh Trivedi, Shivangi Oberai, Prashanth Chakrapani, Minghao Dang, Nancy Milam, Mark E Maynard, Brian D Vaillant, Jason T Huse and 3 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 9 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Mekenzie M PeshoffDepartment of Translational Molecular Pathology at the University of Texas MD Anderson Cancer Center, Houston, TX.
Pravesh GuptaDepartment of Translational Molecular Pathology at the University of Texas MD Anderson Cancer Center, Houston, TX.
Rakesh TrivediDepartment of Translational Molecular Pathology at the University of Texas MD Anderson Cancer Center, Houston, TX.
Shivangi OberaiDepartment of Translational Molecular Pathology at the University of Texas MD Anderson Cancer Center, Houston, TX.
Prashanth ChakrapaniDepartment of Translational Molecular Pathology at the University of Texas MD Anderson Cancer Center, Houston, TX.
Minghao DangDepartment of Genomic Medicine at the University of Texas MD Anderson Cancer Center, Houston, TX.
Nancy MilamDepartment of Translational Molecular Pathology at the University of Texas MD Anderson Cancer Center, Houston, TX.
Mark E MaynardDepartment of Electrical and Computer Engineering, University of Houston, Houston, TX.
Brian D VaillantDell Medical School, University of Texas at Austin, Austin, TX.
Jason T HuseDepartment of Translational Molecular Pathology at the University of Texas MD Anderson Cancer Center, Houston, TX.
Linghua WangDepartment of Genomic Medicine at the University of Texas MD Anderson Cancer Center, Houston, TX.
Karen Clise-DwyerDepartment of Hematopoietic Biology & Malignancy at the University of Texas MD Anderson Cancer Center, Houston, TX.
Krishna P BhatDepartment of Translational Molecular Pathology at the University of Texas MD Anderson Cancer Center, Houston, TX.
The University of Texas MD Anderson Cancer Center · USThe University of Texas at Austin · USUniversity of Houston · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
Bidirectional interaction of platelets and tumor cells in patients with glioblastomaR01CA225963 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BHAT, KRISHNA PL, SULMAN, ERIK · 2019 to 2023
$2.7M
Developing a NF-κB/GADD45b targeting strategy for glioblastomaR21CA222992 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BHAT, KRISHNA PL · 2019 to 2020
$401k
NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA225963NCI NIH HHS R21 CA222992
6 · The paper itself

Abstract

Glioblastomas (GBMs) are tumors of the central nervous system that remain recalcitrant to both standard of care chemo-radiation and immunotherapies. Emerging approaches to treat GBMs include depletion or re-education of innate immune cells including microglia (MG) and macrophages (MACs). Here we show myeloid cell restricted expression of triggering receptor expressed on myeloid cells 2 (TREM2) across low- and high-grade human gliomas. TREM2 expression did not correlate with immunosuppressive pathways, but rather showed strong positive association with phagocytosis markers such as lysozyme (LYZ) and CD163 in gliomas. In line with these observations in patient tumors,

Indexed as

glioblastomamicrogliaphagocytosisTREM2tumor associated macrophages

Identifiers

PMID37066184
PMCPMC10104029
OpenAlexW4362661711

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.